Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Zhu, Hai‐Dong; Li, Hai-Liang; Huang, Mingsheng; Yang, Wei-Zhu; Yin, Guowen; Zhong, Bin‐Yan; Sun, Junhui; Jin, Zhi‐Cheng; Chen, Jian-Jia; Ge, Naijian; Ding, Wen‐Bin; Li, Wenhui; Huang, Jinhua; Mu, Wei; Gu, Shanzhi; Li, Jiaping; Zhao, Hui; Wen, Shu-Wei; Lei, Yanming; Song, Yusheng; Yuan, Chunwang; Wang, Weidong; Huang, Ming; Zhao, Wei; Wu, Jianbing; Wang, Song; Zhu, Xu; Zhu, Xu; Han, Jian-Jun; Ren, Wei-Xin; Lu, Zaiming; Xing, Wenge; Fan, Yong; Lin, Hai-Lan; Zhang, Zishu; Hu, Wenhao; Tu, Qiang; Tu, Qiang; Su, Hong-Ying; Zheng, Chuan-Sheng; Chen, Yong; Zhao, Xuya; Wang, Qi; Wang, Qi; Zhao, Jinwei; Xu, Jian; Xu, Jian; Wu, Qing-Hua; Niu, Huan-Zhang; Wang, Jian; Dai, Feng; Feng, Duiping; Li, Qing-Dong; Shi, Rong-Shu; Li, Jia-Rui; Yang, Guang; Shi, Hai-Bin; Ji, Jian-Song; Liu, Yue; Cai, Zheng; Song Yang, Po; Zhao, Yang; Zhu, Xiao-Li; Zhu, Xiao-Li; Lu, Li-Gong; Teng, Gao‐Jun; the CHANCE001 Investigators, for

doi:10.1038/s41392-022-01235-0

Public

Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Published in Signal Transduction and Targeted Therapy • Feb 8, 2023

Authors:

Hai‐Dong Zhu

Hai-Liang Li

Mingsheng Huang

Abstract

There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with...

Subject

Medicine

Hazard ratio

Hepatocellular carcinoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!